Z Factor Raises £7M in Series A Funding

Z Factor, a University of Cambridge spin-out focused on developing new drugs for Alpha-1-Antitrypsin Deficiency (AATD), has secured £7 million in Series A funding. The round was led by existing investor Medicxi with participation from Cambridge Enterprise and Cambridge Innovation Capital. Z Factor operates as a virtual biotechnology company, outsourcing its drug discovery and development activities. The company has identified dozens of molecules that can correct the folding defect caused by the Z mutation and plans to use the funding to select the best candidates for human trials, aiming to reach the clinic with its lead candidate in 2019.

Z Factor Raises £7 Million for Alpha-1-Antitrypsin Deficiency Drug Development

Z Factor Limited is a University of Cambridge spin-out engaged in the discovery of new drugs to treat Alpha-1-Antitrypsin Deficiency (AATD). Founded by Jim Huntington, Professor of Molecular Haemostasis at the Cambridge Institute for Medical Research, and joined by David Grainger, Partner at Medicxi and Executive Chairman, Z Factor operates as a virtual biotechnology company, with no internal operations, using an established network of out-sourced drug discovery and development providers, including RxCelerate, co-located on the Babraham campus, just south of Cambridge, UK.

A University of Cambridge spin-out developing new drugs to treat Alpha-1-Antitrypsin Deficiency.

8 years ago

Z Factor Raises £7 Million for Alpha-1-Antitrypsin Deficiency Drug Development

ProblemLife Sciences

Solution

Covered on